BioIntelliSense vs Current Health (2026)
Both put a wearable on the patient and alert clinicians when vital signs drift, and both sell into hospital at home. The difference is who does the watching. BioIntelliSense sells continuous monitoring as a subscription to hospitals that staff their own response. The coin sized BioButton on the chest feeds personal trend notifications to the BioDashboard, and its center of gravity is the general ward, where Houston Methodist runs it across 2,653 non ICU beds with a central command center; it also follows patients home after discharge. Current Health sells the monitoring with the people attached. Its upper arm wearable and peripherals feed a 24/7 command center of its own ED and ICU nurses, backed by kit logistics and program consulting, and its focus has moved to CAR T and bispecific therapy outside the hospital, with hospital at home and drug trials alongside. A health system replacing ward spot checks fits BioIntelliSense; one moving acute or post infusion care into the home without its own night nurses fits Current Health.
- Continuous monitoring on general wards in place of four hourly spot checks, as at Houston Methodist across eight hospitals.
- A rechargeable multi patient BioButton for inpatient units, and a new device sent home with patients at discharge.
- A service level of 99.9 percent of hourly readings delivered each month, with part of the monthly fee returned when delivery falls short.
- A hospital that runs its own command center and wants the data rather than an outside nursing team.
- A 24/7 command center of ED and ICU nurses that triages alarms and escalates to the treating team.
- Outpatient CAR T and bispecific programs, with models for early cytokine release syndrome and virtual neurotoxicity checks.
- Kit logistics from delivery to retrieval and reprocessing, plus scheduling and consulting on program design and payer contracts.
- Oxygen saturation and blood pressure in the monitoring kit, with vital signs and alerts written into Epic, Cerner or Meditech.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BioIntelliSense and Current Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BioIntelliSense | Current Health |
|---|---|---|
| Primary category | Inpatient Deterioration & Risk Monitoring | Remote Monitoring & Chronic Care |
| Founded | Not recorded | 2014 |
| Headquarters | Denver, Colorado, United States | Boston, Massachusetts, United States |
| Website | biointellisense.com | currenthealth.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
BioIntelliSense replaces the four hourly vital signs check with a coin sized BioButton worn on the chest, which records heart rate, respiratory rate, skin temperature, position and activity and notifies clinicians when a patient drifts from their own trend. Hospitals buy it as a subscription for general wards, emergency departments, hospital at home and post acute care, with the BioDashboard from its AlertWatch acquisition as the clinicians' view.
Source: AI Health Index, October 2026
Current Health pairs its own monitoring kit with a staffed command center: an FDA cleared upper arm wearable, plus oxygen saturation, temperature and blood pressure devices chosen per program, streams readings to ED and ICU nurses who triage alarms around the clock. Health systems and drug makers use it for outpatient CAR T and bispecific therapy, hospital at home and trial safety monitoring.
Source: AI Health Index, October 2026
Questions buyers ask
What does each wearable measure?
The BioButton records heart rate and respiratory rate at rest, skin temperature, body position and activity. Current Health's upper arm wearable records respiratory rate, heart rate and its variability, skin temperature, oxygen saturation and movement, and programs add an axillary temperature patch, blood pressure cuff, scale or other devices. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
Who responds to an alert?
With BioIntelliSense the hospital's own clinicians review notifications in the BioDashboard, often from a central command center like Houston Methodist's. Current Health supplies its own 24/7 nurses, licensed in all 50 states, who respond to alarms in a median of 2.3 minutes and escalate to the program's clinicians. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
What evidence does each publish?
BioIntelliSense cites a Journal of Clinical Medicine study of nearly 12,000 ward patients at two hospitals, with length of stay down from 3.07 to 2.75 days at one site, and a Houston Methodist study of 1,120 patients transferred to intensive care that reports a 27 percent lower relative risk of death.
Current Health cites peer reviewed CAR T studies, including 18 of 20 CRS episodes caught a median of seven hours early at Mount Sinai and 97 to 98 percent survival at 30 days across 209 outpatients in Sarah Cannon's network. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Hospital & Unit Operations page.
BioIntelliSense acquired AlertWatch, whose software now runs as the BioDashboard, and its user terms say notifications make no diagnosis and do not decide when a patient needs intervention. Current Health was owned by Best Buy from 2021 to 2025. BioIntelliSense describes its deterioration notifications as algorithmic and rules based; Current Health describes machine learning detection, and its CRS model is in an FDA early engagement program for home use devices rather than cleared.